• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

依奇珠单抗：HIV 阳性银屑病患者的另一种选择。

Ixekizumab: an alternative for HIV-positive psoriasis patients.

机构信息

Department of Dermatology, Ganzhou Municipal Hospital, Ganzhou, Jiangxi Province, 341000, People's Republic of China.

Department of Dermatology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, No.106, Zhongshan Second Road, Guangzhou, Guangdong Province, 510080, People's Republic of China.

出版信息

AIDS Res Ther. 2024 Nov 28;21(1):87. doi: 10.1186/s12981-024-00675-8.

DOI:10.1186/s12981-024-00675-8
PMID:39605044
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11603802/
Abstract

Psoriasis is a recurrent and protracted inflammatory disease. Generalized erythema, plaques, and silvery scales on the surface mainly characterize its skin lesions. Biologics bring new hope to psoriasis patients. However, HIV infection is a major concern before receiving biologics. Here, we present a case of the efficacy and safety of Ixekizumab, an interleukin 17 inhibitor, in the treatment of psoriasis patients living with HIV (PPLHIV).

摘要

银屑病是一种反复发作且病程迁延的炎症性疾病。其皮损的主要特征是皮肤表面出现广泛红斑、斑块和银白色鳞屑。生物制剂为银屑病患者带来了新的希望。然而，在接受生物制剂治疗前，HIV 感染是一个主要关注点。在此，我们报告了一例使用白细胞介素 17 抑制剂依奇珠单抗治疗 HIV 阳性银屑病患者（PPLHIV）的疗效和安全性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca96/11603802/30ed3aef6037/12981_2024_675_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca96/11603802/353abf7f6890/12981_2024_675_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca96/11603802/30ed3aef6037/12981_2024_675_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca96/11603802/353abf7f6890/12981_2024_675_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca96/11603802/30ed3aef6037/12981_2024_675_Fig2_HTML.jpg

相似文献

1
Ixekizumab: an alternative for HIV-positive psoriasis patients.依奇珠单抗：HIV 阳性银屑病患者的另一种选择。
AIDS Res Ther. 2024 Nov 28;21(1):87. doi: 10.1186/s12981-024-00675-8.
2
Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).司库奇尤单抗治疗日本中重度斑块状银屑病、红皮病型银屑病和泛发性脓疱型银屑病患者的疗效和安全性：一项为期52周的开放标签3期研究（UNCOVER-J）的结果
J Dermatol. 2017 Apr;44(4):355-362. doi: 10.1111/1346-8138.13622. Epub 2016 Oct 11.
3
Ixekizumab for the treatment of psoriasis: an update on new data since first approval.依奇珠单抗治疗银屑病：首次批准以来新数据的更新。
Expert Rev Clin Immunol. 2019 Feb;15(2):111-121. doi: 10.1080/1744666X.2019.1559730. Epub 2018 Dec 27.
4
Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.司库奇尤单抗用于治疗中度至重度斑块状银屑病和银屑病关节炎的成人患者。
Expert Rev Clin Pharmacol. 2016 Nov;9(11):1423-1433. doi: 10.1080/17512433.2016.1242409. Epub 2016 Oct 11.
5
Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice.司库奇尤单抗（白细胞介素17A拮抗剂）：真实世界临床实践中的12周疗效和安全性结果
J Cutan Med Surg. 2019 Mar/Apr;23(2):174-177. doi: 10.1177/1203475418814229. Epub 2018 Nov 18.
6
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.在一项慢性斑块型银屑病的 2 期研究中，接受司库奇尤单抗开放性治疗 4 年的疗效和安全性。
J Am Acad Dermatol. 2018 Aug;79(2):294-301.e6. doi: 10.1016/j.jaad.2018.03.047. Epub 2018 Apr 10.
7
Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period.16例老年银屑病患者使用司库奇尤单抗1年的疗效和安全性。
J Eur Acad Dermatol Venereol. 2020 Mar;34(3):e152-e153. doi: 10.1111/jdv.16063. Epub 2020 Jan 19.
8
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy.司库奇尤单抗治疗中重度斑块状银屑病的聚焦：设计、研发及治疗应用
Drug Des Devel Ther. 2017 Jun 2;11:1643-1651. doi: 10.2147/DDDT.S92128. eCollection 2017.
9
No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.无需改变药物类别：在银屑病中，司库奇尤单抗治疗后使用依奇珠单抗。
J Dermatolog Treat. 2019 May;30(3):216-220. doi: 10.1080/09546634.2018.1506081. Epub 2018 Sep 11.
10
A Review of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, for Moderate-to-Severe Plaque Psoriasis.抗白细胞介素-17A单克隆抗体司库奇尤单抗治疗中重度斑块状银屑病的综述
Skin Therapy Lett. 2016 Nov;21(6):1-6.

本文引用的文献

1
Use of biologic treatment in psoriasis patients with HIV: A systematic review.生物治疗在合并人类免疫缺陷病毒（HIV）的银屑病患者中的应用：一项系统评价。
J Am Acad Dermatol. 2024 Jul;91(1):107-108. doi: 10.1016/j.jaad.2024.02.042. Epub 2024 Mar 5.
2
The impact of psoriasis biologic therapy on HIV viral load and CD4 cell counts in HIV-positive individuals: A real-world cohort study.银屑病生物疗法对HIV阳性个体的HIV病毒载量和CD4细胞计数的影响：一项真实世界队列研究。
J Eur Acad Dermatol Venereol. 2023 Mar 10. doi: 10.1111/jdv.19020.
3
Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review.
4例HIV阳性患者的生物治疗：病例系列及文献综述
J Psoriasis Psoriatic Arthritis. 2021 Jan;6(1):19-26. doi: 10.1177/2475530320954279. Epub 2020 Sep 16.
4
Reactivation rates of hepatitis B or C or HIV in patients with psoriasis using biological therapies: a systematic review and meta-analysis.生物治疗银屑病患者乙型肝炎或丙型肝炎或 HIV 的再激活率：系统评价和荟萃分析。
Clin Exp Med. 2023 Jul;23(3):701-715. doi: 10.1007/s10238-022-00827-y. Epub 2022 Apr 30.
5
Use of ixekizumab in an HIV-positive patient with psoriatic arthritis.依奇珠单抗在 HIV 阳性银屑病关节炎患者中的应用。
Int J STD AIDS. 2022 Apr;33(5):519-521. doi: 10.1177/09564624221076289. Epub 2022 Feb 27.
6
Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis.生物制剂治疗与银屑病患者严重感染风险的相关性。
JAMA Dermatol. 2021 Sep 1;157(9):1056-1065. doi: 10.1001/jamadermatol.2021.2599.
7
Use of Anti-IL-17 Monoclonal Antibodies in HIV Patients with Erythrodermic Psoriasis.抗白细胞介素-17单克隆抗体在红皮病型银屑病HIV患者中的应用。
Case Rep Dermatol. 2020 Aug 12;12(2):132-137. doi: 10.1159/000508781. eCollection 2020 May-Aug.
8
Psoriasis in HIV infection: an update.人类免疫缺陷病毒感染中的银屑病：最新进展
Int J STD AIDS. 2019 May;30(6):596-604. doi: 10.1177/0956462419827673. Epub 2019 Feb 27.
9
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.美国皮肤病学会-银屑病基金会联合指南：生物制剂治疗银屑病的管理与治疗。
J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.
10
HIV-associated psoriasis: Epidemiology, pathogenesis, and management.HIV 相关性银屑病：流行病学、发病机制与治疗。
Dermatol Ther. 2019 Mar;32(2):e12806. doi: 10.1111/dth.12806. Epub 2019 Jan 6.